Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01847-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Yue Hou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Chest Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Anti-Bacterial Agents, Mycobacterium Infections, Nontuberculous, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Natural Science Fund.
Abstract (Originalsprache)
Mycobacterium abscessus complex (MABC) is an emerging pathogen with intrinsic multidrug resistance. Genomic sequencing technology has been widely applied to predict bacterial resistance in other bacteria, but the catalog of known resistance-determining genes to explain phenotypic resistance in the MABC is incomplete for many antibiotics. Eighty-one MABC strains were isolated from sputum samples of patients with pulmonary disease in the Beijing Chest Hospital. All isolates were tested for minimum inhibitory concentrations (MICs) to eight antibiotics and underwent whole-genome sequencing (WGS). Of the total 81 MABC isolates, six strains exhibited clarithromycin (CLM) resistance by day 3 in culture, but only one (16.7%, 1/6) contained a mutation in the rrl gene. All M. abscessus strains contained the erm (41)28T (100.0%, 49/49) polymorphism and exhibited CLM-induced resistance after 14 days in culture. Of the 61 imipenem-resistant strains, 12 (19.7%, 12/61) had mutations in the bla gene. Although there were four (4.9%) amikacin-resistant, nine (11.1%) linezolid-resistant, eight (9.9%) clofazimine-resistant, 23 (28.4%) bedaquiline-resistant, and 27 (33.3%) cefoxitin-resistant strains, no known mutations associated with resistance to these antibiotics were found. These results suggest that the explanatory power of known resistance genes for clinical MABC resistance is limited and that other unidentified genes or novel resistance mechanisms may be involved.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Chest Hospital, Capital Medical University, Beijing, China.
- Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
- Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.
- CMBC, Instituto Venezolano de Investigaciones Científicas, IVIC, Caracas, Venezuela.
ORCID-Profile: Yue Hou, Howard E Takiff, Chendi Zhu, Wei Wang, Weimin Li
Förderung
- The National Natural Science Fund
Zitieren
APA
Hou, Y., Pi, R., Jia, J., Wu, Z., Huo, F., Zhou, Y., Jiang, H., Takiff, H. E., Zhu, C., Wang, W., & Li, W. (2025). Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01847-24
Vancouver
Hou Y, Pi R, Jia J, Wu Z, Huo F, Zhou Y, et al. Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01847-24
BibTeX
@article{Hou2025,
author = {Hou, Yue and Pi, Rui and Jia, Junnan and Wu, Zhaojun and Huo, Fengmin and Zhou, Yu and Jiang, Hui and Takiff, Howard E and Zhu, Chendi and Wang, Wei and Li, Weimin},
title = {Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01847-24}
}
EUVIMED